{"cells":[{"cell_type":"markdown","source":["#### TASK WITH DATAFRAME"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"db569e51-97d6-4e20-9aee-502f8fa0149a"}}},{"cell_type":"markdown","source":["Just change the `year` value from dropdown and run the code. It will generate all the required data for that year !"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"b2bc76cd-7574-42a3-9d35-11ea37aeb23f"}}},{"cell_type":"code","source":["dbutils.widgets.dropdown(\"YEAR\", \"2021\", [str(x) for x in ['2019','2020','2021']])\nwidget_year_value = dbutils.widgets.get(\"YEAR\")\nstring_year = widget_year_value"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f160c0bf-0fbf-4977-aeaa-9c92804533ce"}},"outputs":[],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (1)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c2ec2036-8aa2-44b4-b997-b0aabe91be32"}}},{"cell_type":"code","source":["file_path = 'dbfs:/FileStore/tables/clinicaltrial_'+string_year+'.csv'\nclinicaltrial_DF = spark.read.csv(file_path, sep ='|', header = True)\nclinicaltrial_DF.show(truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5647b989-d509-40c0-9fe5-611c0251918f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\n|Id         |Sponsor                                               |Status                |Start   |Completion|Type                            |Submission|Conditions                                                                                           |Interventions                                                         |\n+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\n|NCT02758028|The University of Hong Kong                           |Recruiting            |Aug 2005|Nov 2021  |Interventional                  |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02751957|Duke University                                       |Completed             |Jul 2016|Jul 2020  |Interventional                  |Apr 2016  |Autistic Disorder,Autism Spectrum Disorder                                                           |null                                                                  |\n|NCT02758483|Universidade Federal do Rio de Janeiro                |Completed             |Mar 2017|Jan 2018  |Interventional                  |Apr 2016  |Diabetes Mellitus                                                                                    |null                                                                  |\n|NCT02759848|Istanbul Medeniyet University                         |Completed             |Jan 2012|Dec 2014  |Observational                   |May 2016  |Tuberculosis,Lung Diseases,Pulmonary Disease                                                         |null                                                                  |\n|NCT02758860|University of Roma La Sapienza                        |Active, not recruiting|Jun 2016|Sep 2020  |Observational [Patient Registry]|Apr 2016  |Diverticular Diseases,Diverticulum,Diverticulosis                                                    |null                                                                  |\n|NCT02757209|Consorzio Futuro in Ricerca                           |Completed             |Apr 2016|Jan 2018  |Interventional                  |Apr 2016  |Asthma                                                                                               |Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate|\n|NCT02752438|Ankara University                                     |Unknown status        |May 2016|Jul 2017  |Observational [Patient Registry]|Apr 2016  |Hypoventilation                                                                                      |null                                                                  |\n|NCT02753543|Ruijin Hospital                                       |Unknown status        |Nov 2015|Nov 2019  |Interventional                  |Apr 2016  |Lymphoma                                                                                             |null                                                                  |\n|NCT02757508|Washington University School of Medicine              |Completed             |Mar 2016|Jul 2017  |Interventional                  |Apr 2016  |null                                                                                                 |Vitamins                                                              |\n|NCT02753530|Orphazyme                                             |Completed             |Aug 2017|Jan 2021  |Interventional                  |Apr 2016  |Myositis                                                                                             |null                                                                  |\n|NCT02754817|Novo Nordisk A/S                                      |Completed             |Apr 2016|Oct 2016  |Observational                   |Apr 2016  |Diabetes Mellitus                                                                                    |Liraglutide,Xultophy                                                  |\n|NCT02759276|Daniel Alexandre Bottino                              |Completed             |May 2015|Dec 2015  |Observational                   |Apr 2016  |Hypertension                                                                                         |null                                                                  |\n|NCT02750956|Bulent Ecevit University                              |Completed             |Jun 2015|Mar 2016  |Observational                   |Apr 2016  |Periodontal Diseases                                                                                 |null                                                                  |\n|NCT02752113|Institut f체r Pharmakologie und Pr채ventive Medizin     |Completed             |Apr 2016|May 2019  |Interventional                  |Apr 2016  |Diabetes Mellitus                                                                                    |Metformin,Empagliflozin,Linagliptin                                   |\n|NCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021  |Interventional                  |Jun 2015  |Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones                             |null                                                                  |\n|NCT02755779|Tel Aviv Medical Center                               |Unknown status        |Jun 2016|Jun 2017  |Observational                   |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02750384|Medicines for Malaria Venture                         |Terminated            |May 2016|Jul 2016  |Interventional                  |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02754609|James Cook University, Queensland, Australia          |Completed             |Sep 2016|Oct 2019  |Interventional                  |Apr 2016  |Hookworm Infections,Celiac Disease                                                                   |null                                                                  |\n|NCT02755701|Soonchunhyang University Hospital                     |Unknown status        |Jul 2016|Dec 2018  |Interventional                  |Apr 2016  |Ascites                                                                                              |null                                                                  |\n|NCT02751762|Member Companies of the Opioid PMR Consortium         |Recruiting            |Nov 2017|Oct 2022  |Observational                   |Apr 2016  |Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|null                                                                  |\n+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\n|Id         |Sponsor                                               |Status                |Start   |Completion|Type                            |Submission|Conditions                                                                                           |Interventions                                                         |\n+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\n|NCT02758028|The University of Hong Kong                           |Recruiting            |Aug 2005|Nov 2021  |Interventional                  |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02751957|Duke University                                       |Completed             |Jul 2016|Jul 2020  |Interventional                  |Apr 2016  |Autistic Disorder,Autism Spectrum Disorder                                                           |null                                                                  |\n|NCT02758483|Universidade Federal do Rio de Janeiro                |Completed             |Mar 2017|Jan 2018  |Interventional                  |Apr 2016  |Diabetes Mellitus                                                                                    |null                                                                  |\n|NCT02759848|Istanbul Medeniyet University                         |Completed             |Jan 2012|Dec 2014  |Observational                   |May 2016  |Tuberculosis,Lung Diseases,Pulmonary Disease                                                         |null                                                                  |\n|NCT02758860|University of Roma La Sapienza                        |Active, not recruiting|Jun 2016|Sep 2020  |Observational [Patient Registry]|Apr 2016  |Diverticular Diseases,Diverticulum,Diverticulosis                                                    |null                                                                  |\n|NCT02757209|Consorzio Futuro in Ricerca                           |Completed             |Apr 2016|Jan 2018  |Interventional                  |Apr 2016  |Asthma                                                                                               |Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate|\n|NCT02752438|Ankara University                                     |Unknown status        |May 2016|Jul 2017  |Observational [Patient Registry]|Apr 2016  |Hypoventilation                                                                                      |null                                                                  |\n|NCT02753543|Ruijin Hospital                                       |Unknown status        |Nov 2015|Nov 2019  |Interventional                  |Apr 2016  |Lymphoma                                                                                             |null                                                                  |\n|NCT02757508|Washington University School of Medicine              |Completed             |Mar 2016|Jul 2017  |Interventional                  |Apr 2016  |null                                                                                                 |Vitamins                                                              |\n|NCT02753530|Orphazyme                                             |Completed             |Aug 2017|Jan 2021  |Interventional                  |Apr 2016  |Myositis                                                                                             |null                                                                  |\n|NCT02754817|Novo Nordisk A/S                                      |Completed             |Apr 2016|Oct 2016  |Observational                   |Apr 2016  |Diabetes Mellitus                                                                                    |Liraglutide,Xultophy                                                  |\n|NCT02759276|Daniel Alexandre Bottino                              |Completed             |May 2015|Dec 2015  |Observational                   |Apr 2016  |Hypertension                                                                                         |null                                                                  |\n|NCT02750956|Bulent Ecevit University                              |Completed             |Jun 2015|Mar 2016  |Observational                   |Apr 2016  |Periodontal Diseases                                                                                 |null                                                                  |\n|NCT02752113|Institut f체r Pharmakologie und Pr채ventive Medizin     |Completed             |Apr 2016|May 2019  |Interventional                  |Apr 2016  |Diabetes Mellitus                                                                                    |Metformin,Empagliflozin,Linagliptin                                   |\n|NCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021  |Interventional                  |Jun 2015  |Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones                             |null                                                                  |\n|NCT02755779|Tel Aviv Medical Center                               |Unknown status        |Jun 2016|Jun 2017  |Observational                   |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02750384|Medicines for Malaria Venture                         |Terminated            |May 2016|Jul 2016  |Interventional                  |Apr 2016  |null                                                                                                 |null                                                                  |\n|NCT02754609|James Cook University, Queensland, Australia          |Completed             |Sep 2016|Oct 2019  |Interventional                  |Apr 2016  |Hookworm Infections,Celiac Disease                                                                   |null                                                                  |\n|NCT02755701|Soonchunhyang University Hospital                     |Unknown status        |Jul 2016|Dec 2018  |Interventional                  |Apr 2016  |Ascites                                                                                              |null                                                                  |\n|NCT02751762|Member Companies of the Opioid PMR Consortium         |Recruiting            |Nov 2017|Oct 2022  |Observational                   |Apr 2016  |Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|null                                                                  |\n+-----------+------------------------------------------------------+----------------------+--------+----------+--------------------------------+----------+-----------------------------------------------------------------------------------------------------+----------------------------------------------------------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["clinicaltrial_DF.distinct().count()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1696dc5e-62bb-40c8-9575-24e7ffe74408"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[3]: 387261","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[3]: 387261"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3c69a722-0c77-4575-b8ee-87e9b9313e58"}}},{"cell_type":"code","source":["import pyspark.sql.functions as f\nclinicaltrial_type_DF = clinicaltrial_DF.withColumn(string_year, f.explode(f.split(f.col('Type'), '\\t')))\\\n                        .groupBy(string_year)\\\n                        .count()\\\n                        .sort('count', ascending=False)\n\nclinicaltrial_type_DF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"61e15a22-e021-43e4-bcb1-6d788d7f5fcd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+--------------------------------+------+\n|2021                            |count |\n+--------------------------------+------+\n|Interventional                  |301472|\n|Observational                   |77540 |\n|Observational [Patient Registry]|8180  |\n|Expanded Access                 |69    |\n+--------------------------------+------+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+--------------------------------+------+\n|2021                            |count |\n+--------------------------------+------+\n|Interventional                  |301472|\n|Observational                   |77540 |\n|Observational [Patient Registry]|8180  |\n|Expanded Access                 |69    |\n+--------------------------------+------+\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (3)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ec950405-c315-46b9-ab6d-5c88156cc732"}}},{"cell_type":"code","source":["import pyspark.sql.functions as f\nclinicaltrial_condition_DF = clinicaltrial_DF.withColumn(string_year, f.explode(f.split(f.col('Conditions'), ',')))\\\n                                .groupBy(string_year)\\\n                                .count()\\\n                                .sort('count', ascending=False)\n\nclinicaltrial_condition_DF.show(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a9ca6c66-4a0b-4769-8703-7a05230945cd"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------------+-----+\n|             2021|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------------+-----+\n|             2021|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (4)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4fa45221-b272-459b-ae61-99e5f8105a1b"}}},{"cell_type":"code","source":["import pyspark.sql.functions as f\nclinical_condtions_DF = clinicaltrial_DF.select(f.explode(f.split(f.col('Conditions'), ',')).alias('Conditions'))\nclinical_condtions_DF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c380ff90-890b-4eb6-9a52-7308d72566e5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+------------------------+\n|Conditions              |\n+------------------------+\n|Autistic Disorder       |\n|Autism Spectrum Disorder|\n|Diabetes Mellitus       |\n|Tuberculosis            |\n|Lung Diseases           |\n|Pulmonary Disease       |\n|Diverticular Diseases   |\n|Diverticulum            |\n|Diverticulosis          |\n|Asthma                  |\n|Hypoventilation         |\n|Lymphoma                |\n|Myositis                |\n|Diabetes Mellitus       |\n|Hypertension            |\n|Periodontal Diseases    |\n|Diabetes Mellitus       |\n|Appendicitis            |\n|Stomach Ulcer           |\n|Cholecystolithiasis     |\n+------------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+------------------------+\n|Conditions              |\n+------------------------+\n|Autistic Disorder       |\n|Autism Spectrum Disorder|\n|Diabetes Mellitus       |\n|Tuberculosis            |\n|Lung Diseases           |\n|Pulmonary Disease       |\n|Diverticular Diseases   |\n|Diverticulum            |\n|Diverticulosis          |\n|Asthma                  |\n|Hypoventilation         |\n|Lymphoma                |\n|Myositis                |\n|Diabetes Mellitus       |\n|Hypertension            |\n|Periodontal Diseases    |\n|Diabetes Mellitus       |\n|Appendicitis            |\n|Stomach Ulcer           |\n|Cholecystolithiasis     |\n+------------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["meshDF = spark.read.options(delimiter =\",\").csv('/FileStore/tables/mesh.csv', header = True)\nmeshDF.show(truncate = False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"79eb8b5c-088a-4ea3-89b5-948ddff1c0e3"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------------------+-----------------------+\n|term                  |tree                   |\n+----------------------+-----------------------+\n|Calcimycin            |D03.633.100.221.173    |\n|A-23187               |D03.633.100.221.173    |\n|Temefos               |D02.705.400.625.800    |\n|Temefos               |D02.705.539.345.800    |\n|Temefos               |D02.886.300.692.800    |\n|Abate                 |D02.705.400.625.800    |\n|Abate                 |D02.705.539.345.800    |\n|Abate                 |D02.886.300.692.800    |\n|Difos                 |D02.705.400.625.800    |\n|Difos                 |D02.705.539.345.800    |\n|Difos                 |D02.886.300.692.800    |\n|Abattoirs             |J01.576.423.200.700.100|\n|Abattoirs             |J03.540.020            |\n|Abbreviations as Topic|L01.559.598.400.556.131|\n|Acronyms as Topic     |L01.559.598.400.556.131|\n|Abdomen               |A01.923.047            |\n|Abdomen, Acute        |C23.888.592.612.054.200|\n|Abdomen, Acute        |C23.888.821.030.249    |\n|Abdominal Injuries    |C26.017                |\n|Abdominal Neoplasms   |C04.588.033            |\n+----------------------+-----------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------------------+-----------------------+\n|term                  |tree                   |\n+----------------------+-----------------------+\n|Calcimycin            |D03.633.100.221.173    |\n|A-23187               |D03.633.100.221.173    |\n|Temefos               |D02.705.400.625.800    |\n|Temefos               |D02.705.539.345.800    |\n|Temefos               |D02.886.300.692.800    |\n|Abate                 |D02.705.400.625.800    |\n|Abate                 |D02.705.539.345.800    |\n|Abate                 |D02.886.300.692.800    |\n|Difos                 |D02.705.400.625.800    |\n|Difos                 |D02.705.539.345.800    |\n|Difos                 |D02.886.300.692.800    |\n|Abattoirs             |J01.576.423.200.700.100|\n|Abattoirs             |J03.540.020            |\n|Abbreviations as Topic|L01.559.598.400.556.131|\n|Acronyms as Topic     |L01.559.598.400.556.131|\n|Abdomen               |A01.923.047            |\n|Abdomen, Acute        |C23.888.592.612.054.200|\n|Abdomen, Acute        |C23.888.821.030.249    |\n|Abdominal Injuries    |C26.017                |\n|Abdominal Neoplasms   |C04.588.033            |\n+----------------------+-----------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["meshTreeCustomDF = meshDF.withColumn('custom_tree', meshDF.tree[0:3])\nmeshTreeCustomDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8806a845-97be-4cae-ab8f-61325a05b26f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------------------+-----------------------+-----------+\n|term                  |tree                   |custom_tree|\n+----------------------+-----------------------+-----------+\n|Calcimycin            |D03.633.100.221.173    |D03        |\n|A-23187               |D03.633.100.221.173    |D03        |\n|Temefos               |D02.705.400.625.800    |D02        |\n|Temefos               |D02.705.539.345.800    |D02        |\n|Temefos               |D02.886.300.692.800    |D02        |\n|Abate                 |D02.705.400.625.800    |D02        |\n|Abate                 |D02.705.539.345.800    |D02        |\n|Abate                 |D02.886.300.692.800    |D02        |\n|Difos                 |D02.705.400.625.800    |D02        |\n|Difos                 |D02.705.539.345.800    |D02        |\n|Difos                 |D02.886.300.692.800    |D02        |\n|Abattoirs             |J01.576.423.200.700.100|J01        |\n|Abattoirs             |J03.540.020            |J03        |\n|Abbreviations as Topic|L01.559.598.400.556.131|L01        |\n|Acronyms as Topic     |L01.559.598.400.556.131|L01        |\n|Abdomen               |A01.923.047            |A01        |\n|Abdomen, Acute        |C23.888.592.612.054.200|C23        |\n|Abdomen, Acute        |C23.888.821.030.249    |C23        |\n|Abdominal Injuries    |C26.017                |C26        |\n|Abdominal Neoplasms   |C04.588.033            |C04        |\n+----------------------+-----------------------+-----------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------------------+-----------------------+-----------+\n|term                  |tree                   |custom_tree|\n+----------------------+-----------------------+-----------+\n|Calcimycin            |D03.633.100.221.173    |D03        |\n|A-23187               |D03.633.100.221.173    |D03        |\n|Temefos               |D02.705.400.625.800    |D02        |\n|Temefos               |D02.705.539.345.800    |D02        |\n|Temefos               |D02.886.300.692.800    |D02        |\n|Abate                 |D02.705.400.625.800    |D02        |\n|Abate                 |D02.705.539.345.800    |D02        |\n|Abate                 |D02.886.300.692.800    |D02        |\n|Difos                 |D02.705.400.625.800    |D02        |\n|Difos                 |D02.705.539.345.800    |D02        |\n|Difos                 |D02.886.300.692.800    |D02        |\n|Abattoirs             |J01.576.423.200.700.100|J01        |\n|Abattoirs             |J03.540.020            |J03        |\n|Abbreviations as Topic|L01.559.598.400.556.131|L01        |\n|Acronyms as Topic     |L01.559.598.400.556.131|L01        |\n|Abdomen               |A01.923.047            |A01        |\n|Abdomen, Acute        |C23.888.592.612.054.200|C23        |\n|Abdomen, Acute        |C23.888.821.030.249    |C23        |\n|Abdominal Injuries    |C26.017                |C26        |\n|Abdominal Neoplasms   |C04.588.033            |C04        |\n+----------------------+-----------------------+-----------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["joinedDF = clinical_condtions_DF.join(meshTreeCustomDF,clinical_condtions_DF.Conditions == meshTreeCustomDF.term, \"inner\")\njoinedDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5e0589f4-e906-434c-a921-cff6b055a8da"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------+-------+-----------+-----------+\n|Conditions|term   |tree       |custom_tree|\n+----------+-------+-----------+-----------+\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n+----------+-------+-----------+-----------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------+-------+-----------+-----------+\n|Conditions|term   |tree       |custom_tree|\n+----------+-------+-----------+-----------+\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n|Abdomen   |Abdomen|A01.923.047|A01        |\n+----------+-------+-----------+-----------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import pyspark.sql.functions as f\nmesh_tree_count_DF = joinedDF.withColumn(string_year, f.explode(f.split(f.col('custom_tree'), '\\t')))\\\n                    .groupBy(string_year)\\\n                    .count()\\\n                    .sort('count', ascending=False)\n                    \nmesh_tree_count_DF.show(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3e773eb4-91ef-4b64-9503-1d76c1490650"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----+------+\n|2021| count|\n+----+------+\n| C04|143994|\n| C23|136079|\n| C01|106674|\n| C14| 94523|\n| C10| 92310|\n| C06| 85646|\n| C08| 70720|\n| C13| 42599|\n| C18| 41276|\n| C12| 40161|\n+----+------+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----+------+\n|2021| count|\n+----+------+\n| C04|143994|\n| C23|136079|\n| C01|106674|\n| C14| 94523|\n| C10| 92310|\n| C06| 85646|\n| C08| 70720|\n| C13| 42599|\n| C18| 41276|\n| C12| 40161|\n+----+------+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ccf64ddc-02b6-4758-b97c-b4fa1338cd37"}}},{"cell_type":"code","source":["pharmaDF = spark.read.options(delimiter =\",\").csv('/FileStore/tables/pharma.csv', header = True)\npharmaDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3221fc46-5ae4-4b9a-905e-2916f5e64180"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Company                                                    |Parent_Company        |Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group                          |Primary_Offense                                      |Secondary_Offense                                    |Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Level_of_Government|Action_Type  |Agency                                                         |Civil/Criminal    |Prosecution_Agreement|Court|Case_ID        |Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City        |Address             |Zip  |NAICS_Code|NAICS_Translation                                                                |HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source                                                                                                                                               |Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Abbott Laboratories                                        |Abbott Laboratories   |$5,475,000    |$0                      |$5,475,000                                               |2013        |20131227    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.                                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians                                   |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.                                   |AbbVie                |$1,500,000,000|$0                      |$1,500,000,000                                           |2012        |20120507    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.|federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote                                   |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.                                   |AbbVie                |$126,500,000  |$0                      |$126,500,000                                             |2010        |20101207    |government-contracting-related offenses|False Claims Act and related                         |null                                                 |Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.                                                                                                                                                                                                                                                |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases                                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Puerto Rico, Inc.                      |Abbott Laboratories   |$49,045       |$0                      |$49,045                                                  |2009        |20090305    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act                             |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1527129        |null                         |null              |Puerto Rico   |San Juan    |null                |null |423450    |423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers|USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Acclarent Inc.                                             |Johnson & Johnson     |$18,000,000   |$0                      |$18,000,000                                              |2016        |20160722    |government-contracting-related offenses|False Claims Act and related                         |null                                                 |California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.                                                                                                                                                                                                                                                    |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Medical Optics                                    |Abbott Laboratories   |$16,800       |$0                      |$16,800                                                  |2004        |20040412    |employment-related offenses            |labor relations violation                            |null                                                 |back pay award in unfair labor practices case                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |federal            |agency action|National Labor Relations Board                                 |civil             |null                 |null |21-CA-36104-001|null                         |null              |California    |Irvine      |null                |92606|333314    |333314: Optical Instrument and Lens Manufacturing                                |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Neuromodulation Systems, Inc.                     |Abbott Laboratories   |$2,950,000    |$0                      |$2,950,000                                               |2007        |20070702    |healthcare-related offenses            |HHS civil monetary penalties                         |kickbacks and bribery                                |The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.                                                                                                                                                                                                                                                             |federal            |agency action|Health & Human Services Department Office of Inspector General |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf                                                                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Sterilization Products                            |Johnson & Johnson     |$136,800      |$0                      |$136,800                                                 |2014        |20140520    |environment-related offenses           |environmental violation                              |null                                                 |The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.                                                                                                                                                                                                                                                                                                                                                                                 |federal            |agency action|Environmental Protection Agency                                |civil             |null                 |null |null           |null                         |null              |California    |Irvine      |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html                                                      |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Sterilization Products, a division of Ethicon Inc.|Johnson & Johnson     |$1,200,000    |$0                      |$1,200,000                                               |2013        |20131204    |safety-related offenses                |drug or medical equipment safety violation           |null                                                 |Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.                                                                                                                                                                                                                                                    \n\n*** WARNING: max output size exceeded, skipping output. ***\n\n                |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Allergan Inc.                                              |AbbVie                |$600,000,000  |$0                      |$600,000,000                                             |2010        |20100901    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.                                                                                                                                                                         |federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox                                  |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Allergan Inc.                                              |AbbVie                |$15,000,000   |$0                      |$15,000,000                                              |2017        |20170117    |financial offenses                     |investor protection violation                        |null                                                 |Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |federal            |agency action|Securities and Exchange Commission                             |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.sec.gov/news/pressrelease/2017-16.html                                                                                                        |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Alpharma Inc.                                              |Pfizer                |$42,500,000   |$0                      |$42,500,000                                              |2010        |20100316    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug.                                                                                                                                                                                                                                                              |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New York          |publicly traded    |PFE                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug                                    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Alpharma, Inc.                                             |Pfizer                |$2,500,000    |$0                      |$2,500,000                                               |2004        |20040812    |competition-related offenses           |price-fixing or anti-competitive practices           |consumer protection violation                        |Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.                                                                                                                                                                                                                                                                                                                                          |federal            |agency action|Federal Trade Commission                                       |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New York          |publicly traded    |PFE                        |pharmaceuticals         |pharmaceuticals            |https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges                                                          |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|American Pharmaceutical Partners, Inc.                     |Bristol-Myers Squibb  |$160,203      |$0                      |$160,203                                                 |2004        |20041226    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act                             |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1379241        |null                         |null              |New York      |Grand Island|null                |14072|32541     |32541: Pharmaceutical and Medicine Manufacturing                                 |USA                 |New York          |publicly traded    |BMY                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Amgen Inc.                                                 |Amgen                 |$762,000,000  |$0                      |$762,000,000                                             |2012        |20121219    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.                                                                                                                                                                                                                                                                            |federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal                                        |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amgen Inc.                                                 |Amgen                 |$24,900,000   |$0                      |$24,900,000                                              |2013        |20130416    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen's Aranesp.\"                                                                                                                                                                                                             |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations                                                              |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amgen, Inc.                                                |Amgen                 |$40,000       |$0                      |$40,000                                                  |2011        |20110302    |employment-related offenses            |labor relations violation                            |null                                                 |back pay award in unfair labor practices case                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |federal            |agency action|National Labor Relations Board                                 |civil             |null                 |null |14-CA-30273-001|null                         |null              |Missouri      |St. Louis   |null                |63130|541720    |541720: Research and Development in the Social Sciences and Humanities           |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amneal Pharmaceuticals of NY, LLC                          |Amneal Pharmaceuticals|$99,000       |$0                      |$99,000                                                  |2015        |20150930    |employment-related offenses            |employment discrimination                            |null                                                 |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Office of Federal Contract Compliance Programs                 |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |AMRX                       |pharmaceuticals         |pharmaceuticals            |https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf                                                                                 |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Astellas Pharma US Inc.                                    |Astellas Pharma       |$7,300,000    |$0                      |$7,300,000                                               |2014        |20140416    |government-contracting-related offenses|False Claims Act and related                         |off-label or unapproved promotion of medical products|Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |Japan               |null              |publicly traded    |null                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing                              |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Company                                                    |Parent_Company        |Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|Offense_Group                          |Primary_Offense                                      |Secondary_Offense                                    |Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |Level_of_Government|Action_Type  |Agency                                                         |Civil/Criminal    |Prosecution_Agreement|Court|Case_ID        |Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|City        |Address             |Zip  |NAICS_Code|NAICS_Translation                                                                |HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|Info_Source                                                                                                                                               |Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|Abbott Laboratories                                        |Abbott Laboratories   |$5,475,000    |$0                      |$5,475,000                                               |2013        |20131227    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.                                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians                                   |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.                                   |AbbVie                |$1,500,000,000|$0                      |$1,500,000,000                                           |2012        |20120507    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.|federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote                                   |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Inc.                                   |AbbVie                |$126,500,000  |$0                      |$126,500,000                                             |2010        |20101207    |government-contracting-related offenses|False Claims Act and related                         |null                                                 |Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.                                                                                                                                                                                                                                                |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases                                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Abbott Laboratories Puerto Rico, Inc.                      |Abbott Laboratories   |$49,045       |$0                      |$49,045                                                  |2009        |20090305    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act                             |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1527129        |null                         |null              |Puerto Rico   |San Juan    |null                |null |423450    |423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers|USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Acclarent Inc.                                             |Johnson & Johnson     |$18,000,000   |$0                      |$18,000,000                                              |2016        |20160722    |government-contracting-related offenses|False Claims Act and related                         |null                                                 |California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.                                                                                                                                                                                                                                                    |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Medical Optics                                    |Abbott Laboratories   |$16,800       |$0                      |$16,800                                                  |2004        |20040412    |employment-related offenses            |labor relations violation                            |null                                                 |back pay award in unfair labor practices case                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |federal            |agency action|National Labor Relations Board                                 |civil             |null                 |null |21-CA-36104-001|null                         |null              |California    |Irvine      |null                |92606|333314    |333314: Optical Instrument and Lens Manufacturing                                |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Neuromodulation Systems, Inc.                     |Abbott Laboratories   |$2,950,000    |$0                      |$2,950,000                                               |2007        |20070702    |healthcare-related offenses            |HHS civil monetary penalties                         |kickbacks and bribery                                |The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.                                                                                                                                                                                                                                                             |federal            |agency action|Health & Human Services Department Office of Inspector General |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf                                                                                |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Sterilization Products                            |Johnson & Johnson     |$136,800      |$0                      |$136,800                                                 |2014        |20140520    |environment-related offenses           |environmental violation                              |null                                                 |The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.                                                                                                                                                                                                                                                                                                                                                                                 |federal            |agency action|Environmental Protection Agency                                |civil             |null                 |null |null           |null                         |null              |California    |Irvine      |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |JNJ                        |pharmaceuticals         |pharmaceuticals            |https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html                                                      |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Advanced Sterilization Products, a division of Ethicon Inc.|Johnson & Johnson     |$1,200,000    |$0                      |$1,200,000                                               |2013        |20131204    |safety-related offenses                |drug or medical equipment safety violation           |null                                                 |Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.                                                                                                                                                                                                                                                    \n\n*** WARNING: max output size exceeded, skipping output. ***\n\n                |USA                 |Illinois          |publicly traded    |ABT                        |pharmaceuticals         |pharmaceuticals            |July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Allergan Inc.                                              |AbbVie                |$600,000,000  |$0                      |$600,000,000                                             |2010        |20100901    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.                                                                                                                                                                         |federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox                                  |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Allergan Inc.                                              |AbbVie                |$15,000,000   |$0                      |$15,000,000                                              |2017        |20170117    |financial offenses                     |investor protection violation                        |null                                                 |Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |federal            |agency action|Securities and Exchange Commission                             |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |Illinois          |publicly traded    |ABBV                       |pharmaceuticals         |pharmaceuticals            |https://www.sec.gov/news/pressrelease/2017-16.html                                                                                                        |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Alpharma Inc.                                              |Pfizer                |$42,500,000   |$0                      |$42,500,000                                              |2010        |20100316    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug.                                                                                                                                                                                                                                                              |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New York          |publicly traded    |PFE                        |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug                                    |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Alpharma, Inc.                                             |Pfizer                |$2,500,000    |$0                      |$2,500,000                                               |2004        |20040812    |competition-related offenses           |price-fixing or anti-competitive practices           |consumer protection violation                        |Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.                                                                                                                                                                                                                                                                                                                                          |federal            |agency action|Federal Trade Commission                                       |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New York          |publicly traded    |PFE                        |pharmaceuticals         |pharmaceuticals            |https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges                                                          |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|American Pharmaceutical Partners, Inc.                     |Bristol-Myers Squibb  |$160,203      |$0                      |$160,203                                                 |2004        |20041226    |employment-related offenses            |wage and hour violation                              |Fair Labor Standards Act                             |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Labor Department Wage and Hour Division                        |civil             |null                 |null |1379241        |null                         |null              |New York      |Grand Island|null                |14072|32541     |32541: Pharmaceutical and Medicine Manufacturing                                 |USA                 |New York          |publicly traded    |BMY                        |pharmaceuticals         |pharmaceuticals            |March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php                            |Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.|\n|Amgen Inc.                                                 |Amgen                 |$762,000,000  |$0                      |$762,000,000                                             |2012        |20121219    |healthcare-related offenses            |off-label or unapproved promotion of medical products|null                                                 |U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.                                                                                                                                                                                                                                                                            |federal            |agency action|Food and Drug Administration referral to the Justice Department|civil and criminal|null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal                                        |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amgen Inc.                                                 |Amgen                 |$24,900,000   |$0                      |$24,900,000                                              |2013        |20130416    |government-contracting-related offenses|False Claims Act and related                         |kickbacks and bribery                                |\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen's Aranesp.\"                                                                                                                                                                                                             |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations                                                              |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amgen, Inc.                                                |Amgen                 |$40,000       |$0                      |$40,000                                                  |2011        |20110302    |employment-related offenses            |labor relations violation                            |null                                                 |back pay award in unfair labor practices case                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |federal            |agency action|National Labor Relations Board                                 |civil             |null                 |null |14-CA-30273-001|null                         |null              |Missouri      |St. Louis   |null                |63130|541720    |541720: Research and Development in the Social Sciences and Humanities           |USA                 |California        |publicly traded    |AMGN                       |pharmaceuticals         |pharmaceuticals            |Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml|null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Amneal Pharmaceuticals of NY, LLC                          |Amneal Pharmaceuticals|$99,000       |$0                      |$99,000                                                  |2015        |20150930    |employment-related offenses            |employment discrimination                            |null                                                 |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |federal            |agency action|Office of Federal Contract Compliance Programs                 |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |USA                 |New Jersey        |publicly traded    |AMRX                       |pharmaceuticals         |pharmaceuticals            |https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf                                                                                 |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|Astellas Pharma US Inc.                                    |Astellas Pharma       |$7,300,000    |$0                      |$7,300,000                                               |2014        |20140416    |government-contracting-related offenses|False Claims Act and related                         |off-label or unapproved promotion of medical products|Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.                                                                                                                                                                                                                                                                                                                                                                                                                         |federal            |agency action|Justice Department Civil Division                              |civil             |null                 |null |null           |null                         |null              |null          |null        |null                |null |null      |null                                                                             |Japan               |null              |publicly traded    |null                       |pharmaceuticals         |pharmaceuticals            |https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing                              |null                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+-----------------------------------------------------------+----------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+---------------------------------------+-----------------------------------------------------+-----------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------+-------------+---------------------------------------------------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+------------+--------------------+-----+----------+---------------------------------------------------------------------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import pyspark.sql.functions as f\nparent_companyDF = pharmaDF.select(f.explode(f.split(f.col('Parent_Company'), '\\t')).alias('Parent_Company'))\nparent_companyDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"26366a6e-eea5-465c-b298-3f89886e8df4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------------------+\n|Parent_Company        |\n+----------------------+\n|Abbott Laboratories   |\n|AbbVie                |\n|AbbVie                |\n|Abbott Laboratories   |\n|Johnson & Johnson     |\n|Abbott Laboratories   |\n|Abbott Laboratories   |\n|Johnson & Johnson     |\n|Johnson & Johnson     |\n|Abbott Laboratories   |\n|AbbVie                |\n|AbbVie                |\n|Pfizer                |\n|Pfizer                |\n|Bristol-Myers Squibb  |\n|Amgen                 |\n|Amgen                 |\n|Amgen                 |\n|Amneal Pharmaceuticals|\n|Astellas Pharma       |\n+----------------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------------------+\n|Parent_Company        |\n+----------------------+\n|Abbott Laboratories   |\n|AbbVie                |\n|AbbVie                |\n|Abbott Laboratories   |\n|Johnson & Johnson     |\n|Abbott Laboratories   |\n|Abbott Laboratories   |\n|Johnson & Johnson     |\n|Johnson & Johnson     |\n|Abbott Laboratories   |\n|AbbVie                |\n|AbbVie                |\n|Pfizer                |\n|Pfizer                |\n|Bristol-Myers Squibb  |\n|Amgen                 |\n|Amgen                 |\n|Amgen                 |\n|Amneal Pharmaceuticals|\n|Astellas Pharma       |\n+----------------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["clinical_sponsors_DF = clinicaltrial_DF.select(f.explode(f.split(f.col('Sponsor'), '\\t')).alias('Sponsor'))"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4d89a727-d21d-4f85-b23b-be4af25b935f"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["joinClinicPharmaDF = clinical_sponsors_DF.join(parent_companyDF, clinical_sponsors_DF.Sponsor == parent_companyDF.Parent_Company, \"left\")"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"a91bbe77-a3f3-4d35-8cba-c2289b6f3b6b"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["joinClinicPharmaFilterDF = joinClinicPharmaDF.filter(joinClinicPharmaDF.Parent_Company.isNull())"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5a09528b-6d22-49cd-9247-cd664fbbbc07"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["joinClinicPharmaFilterDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1d927c33-afaf-4b00-826f-431187fc7012"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+------------------------------------------------------+--------------+\n|Sponsor                                               |Parent_Company|\n+------------------------------------------------------+--------------+\n|The University of Hong Kong                           |null          |\n|Duke University                                       |null          |\n|Universidade Federal do Rio de Janeiro                |null          |\n|Istanbul Medeniyet University                         |null          |\n|University of Roma La Sapienza                        |null          |\n|Consorzio Futuro in Ricerca                           |null          |\n|Ankara University                                     |null          |\n|Ruijin Hospital                                       |null          |\n|Washington University School of Medicine              |null          |\n|Orphazyme                                             |null          |\n|Novo Nordisk A/S                                      |null          |\n|Daniel Alexandre Bottino                              |null          |\n|Bulent Ecevit University                              |null          |\n|Institut f체r Pharmakologie und Pr채ventive Medizin     |null          |\n|The Third Xiangya Hospital of Central South University|null          |\n|Tel Aviv Medical Center                               |null          |\n|Medicines for Malaria Venture                         |null          |\n|James Cook University, Queensland, Australia          |null          |\n|Soonchunhyang University Hospital                     |null          |\n|Member Companies of the Opioid PMR Consortium         |null          |\n+------------------------------------------------------+--------------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+------------------------------------------------------+--------------+\n|Sponsor                                               |Parent_Company|\n+------------------------------------------------------+--------------+\n|The University of Hong Kong                           |null          |\n|Duke University                                       |null          |\n|Universidade Federal do Rio de Janeiro                |null          |\n|Istanbul Medeniyet University                         |null          |\n|University of Roma La Sapienza                        |null          |\n|Consorzio Futuro in Ricerca                           |null          |\n|Ankara University                                     |null          |\n|Ruijin Hospital                                       |null          |\n|Washington University School of Medicine              |null          |\n|Orphazyme                                             |null          |\n|Novo Nordisk A/S                                      |null          |\n|Daniel Alexandre Bottino                              |null          |\n|Bulent Ecevit University                              |null          |\n|Institut f체r Pharmakologie und Pr채ventive Medizin     |null          |\n|The Third Xiangya Hospital of Central South University|null          |\n|Tel Aviv Medical Center                               |null          |\n|Medicines for Malaria Venture                         |null          |\n|James Cook University, Queensland, Australia          |null          |\n|Soonchunhyang University Hospital                     |null          |\n|Member Companies of the Opioid PMR Consortium         |null          |\n+------------------------------------------------------+--------------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import pyspark.sql.functions as f\njoinClinicPharmaFilterDF.withColumn(string_year, f.explode(f.split(f.col('Sponsor'), '\\t')))\\\n    .groupBy(string_year)\\\n    .count()\\\n    .sort('count', ascending=False)\\\n    .show(10,truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ac63dc94-5097-47a2-8930-2979a20b0246"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+---------------------------------------+-----+\n|2021                                   |count|\n+---------------------------------------+-----+\n|National Cancer Institute (NCI)        |3218 |\n|M.D. Anderson Cancer Center            |2414 |\n|Assistance Publique - H척pitaux de Paris|2369 |\n|Mayo Clinic                            |2300 |\n|Merck Sharp & Dohme Corp.              |2243 |\n|Assiut University                      |2154 |\n|Novartis Pharmaceuticals               |2088 |\n|Massachusetts General Hospital         |1971 |\n|Cairo University                       |1928 |\n|Hoffmann-La Roche                      |1828 |\n+---------------------------------------+-----+\nonly showing top 10 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+---------------------------------------+-----+\n|2021                                   |count|\n+---------------------------------------+-----+\n|National Cancer Institute (NCI)        |3218 |\n|M.D. Anderson Cancer Center            |2414 |\n|Assistance Publique - H척pitaux de Paris|2369 |\n|Mayo Clinic                            |2300 |\n|Merck Sharp & Dohme Corp.              |2243 |\n|Assiut University                      |2154 |\n|Novartis Pharmaceuticals               |2088 |\n|Massachusetts General Hospital         |1971 |\n|Cairo University                       |1928 |\n|Hoffmann-La Roche                      |1828 |\n+---------------------------------------+-----+\nonly showing top 10 rows\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Problem Number (6)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f67411b9-bead-483c-aad4-c9bc3a83fe6f"}}},{"cell_type":"code","source":["completed_studies = clinicaltrial_DF.select('Status', 'Completion').where(clinicaltrial_DF.Status == 'Completed')"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"70aec4a1-dca8-4fbd-8760-824278a2fb95"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["completed_studies.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1c9c7bf1-e874-4efc-885c-750cd1ef4150"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+---------+----------+\n|Status   |Completion|\n+---------+----------+\n|Completed|Jul 2020  |\n|Completed|Jan 2018  |\n|Completed|Dec 2014  |\n|Completed|Jan 2018  |\n|Completed|Jul 2017  |\n|Completed|Jan 2021  |\n|Completed|Oct 2016  |\n|Completed|Dec 2015  |\n|Completed|Mar 2016  |\n|Completed|May 2019  |\n|Completed|Oct 2019  |\n|Completed|Apr 2015  |\n|Completed|Jan 2016  |\n|Completed|null      |\n|Completed|Apr 2017  |\n|Completed|Nov 2020  |\n|Completed|Jul 2017  |\n|Completed|Jun 2021  |\n|Completed|Mar 2017  |\n|Completed|Apr 2018  |\n+---------+----------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+---------+----------+\n|Status   |Completion|\n+---------+----------+\n|Completed|Jul 2020  |\n|Completed|Jan 2018  |\n|Completed|Dec 2014  |\n|Completed|Jan 2018  |\n|Completed|Jul 2017  |\n|Completed|Jan 2021  |\n|Completed|Oct 2016  |\n|Completed|Dec 2015  |\n|Completed|Mar 2016  |\n|Completed|May 2019  |\n|Completed|Oct 2019  |\n|Completed|Apr 2015  |\n|Completed|Jan 2016  |\n|Completed|null      |\n|Completed|Apr 2017  |\n|Completed|Nov 2020  |\n|Completed|Jul 2017  |\n|Completed|Jun 2021  |\n|Completed|Mar 2017  |\n|Completed|Apr 2018  |\n+---------+----------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["import pyspark.sql.functions as f\nsplit_col = f.split(completed_studies['Completion'], ' ')\ncompleted_studies = completed_studies.withColumn('completion_month', split_col.getItem(0))\ncompleted_studies = completed_studies.withColumn('completion_year', split_col.getItem(1))\ncompleted_studies = completed_studies.withColumn(\"issue_month\", f.from_unixtime(f.unix_timestamp(f.col(\"Completion\"),'MMM yyyy'),'MM'))"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f85d5548-bb15-4d8c-ba50-4e8c7f522a30"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["completed_studies.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1eb90840-163f-4741-b14a-072084073cfa"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+---------+----------+----------------+---------------+-----------+\n|Status   |Completion|completion_month|completion_year|issue_month|\n+---------+----------+----------------+---------------+-----------+\n|Completed|Jul 2020  |Jul             |2020           |07         |\n|Completed|Jan 2018  |Jan             |2018           |01         |\n|Completed|Dec 2014  |Dec             |2014           |12         |\n|Completed|Jan 2018  |Jan             |2018           |01         |\n|Completed|Jul 2017  |Jul             |2017           |07         |\n|Completed|Jan 2021  |Jan             |2021           |01         |\n|Completed|Oct 2016  |Oct             |2016           |10         |\n|Completed|Dec 2015  |Dec             |2015           |12         |\n|Completed|Mar 2016  |Mar             |2016           |03         |\n|Completed|May 2019  |May             |2019           |05         |\n|Completed|Oct 2019  |Oct             |2019           |10         |\n|Completed|Apr 2015  |Apr             |2015           |04         |\n|Completed|Jan 2016  |Jan             |2016           |01         |\n|Completed|null      |null            |null           |null       |\n|Completed|Apr 2017  |Apr             |2017           |04         |\n|Completed|Nov 2020  |Nov             |2020           |11         |\n|Completed|Jul 2017  |Jul             |2017           |07         |\n|Completed|Jun 2021  |Jun             |2021           |06         |\n|Completed|Mar 2017  |Mar             |2017           |03         |\n|Completed|Apr 2018  |Apr             |2018           |04         |\n+---------+----------+----------------+---------------+-----------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+---------+----------+----------------+---------------+-----------+\n|Status   |Completion|completion_month|completion_year|issue_month|\n+---------+----------+----------------+---------------+-----------+\n|Completed|Jul 2020  |Jul             |2020           |07         |\n|Completed|Jan 2018  |Jan             |2018           |01         |\n|Completed|Dec 2014  |Dec             |2014           |12         |\n|Completed|Jan 2018  |Jan             |2018           |01         |\n|Completed|Jul 2017  |Jul             |2017           |07         |\n|Completed|Jan 2021  |Jan             |2021           |01         |\n|Completed|Oct 2016  |Oct             |2016           |10         |\n|Completed|Dec 2015  |Dec             |2015           |12         |\n|Completed|Mar 2016  |Mar             |2016           |03         |\n|Completed|May 2019  |May             |2019           |05         |\n|Completed|Oct 2019  |Oct             |2019           |10         |\n|Completed|Apr 2015  |Apr             |2015           |04         |\n|Completed|Jan 2016  |Jan             |2016           |01         |\n|Completed|null      |null            |null           |null       |\n|Completed|Apr 2017  |Apr             |2017           |04         |\n|Completed|Nov 2020  |Nov             |2020           |11         |\n|Completed|Jul 2017  |Jul             |2017           |07         |\n|Completed|Jun 2021  |Jun             |2021           |06         |\n|Completed|Mar 2017  |Mar             |2017           |03         |\n|Completed|Apr 2018  |Apr             |2018           |04         |\n+---------+----------+----------------+---------------+-----------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["completed_studies_filterDF = completed_studies.select('completion_month', 'completion_year', 'issue_month').filter(completed_studies.completion_year == string_year)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"aa9409ae-988d-4e94-ad0b-d94c56a4e002"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["completed_studies_filterDF.show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"beba54e3-5171-49fd-b870-4022324a5d8e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------------+---------------+-----------+\n|completion_month|completion_year|issue_month|\n+----------------+---------------+-----------+\n|Jan             |2021           |01         |\n|Jun             |2021           |06         |\n|Mar             |2021           |03         |\n|Jan             |2021           |01         |\n|May             |2021           |05         |\n|Feb             |2021           |02         |\n|Feb             |2021           |02         |\n|May             |2021           |05         |\n|Aug             |2021           |08         |\n|May             |2021           |05         |\n|Mar             |2021           |03         |\n|Feb             |2021           |02         |\n|May             |2021           |05         |\n|May             |2021           |05         |\n|May             |2021           |05         |\n|Apr             |2021           |04         |\n|Apr             |2021           |04         |\n|Aug             |2021           |08         |\n|Feb             |2021           |02         |\n|Apr             |2021           |04         |\n+----------------+---------------+-----------+\nonly showing top 20 rows\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------------+---------------+-----------+\n|completion_month|completion_year|issue_month|\n+----------------+---------------+-----------+\n|Jan             |2021           |01         |\n|Jun             |2021           |06         |\n|Mar             |2021           |03         |\n|Jan             |2021           |01         |\n|May             |2021           |05         |\n|Feb             |2021           |02         |\n|Feb             |2021           |02         |\n|May             |2021           |05         |\n|Aug             |2021           |08         |\n|May             |2021           |05         |\n|Mar             |2021           |03         |\n|Feb             |2021           |02         |\n|May             |2021           |05         |\n|May             |2021           |05         |\n|May             |2021           |05         |\n|Apr             |2021           |04         |\n|Apr             |2021           |04         |\n|Aug             |2021           |08         |\n|Feb             |2021           |02         |\n|Apr             |2021           |04         |\n+----------------+---------------+-----------+\nonly showing top 20 rows\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["sorted_completed_studiesDF = completed_studies_filterDF.select('completion_month', 'issue_month')\\\n                                    .groupBy('completion_month', 'issue_month')\\\n                                    .count()\\\n                                    .sort('issue_month')"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"22396d5a-3f92-4ede-bc90-43233ed0a4e9"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["sorted_completed_studiesDF.printSchema()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cdfa4570-36fc-444c-9e59-0be255739519"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"root\n |-- completion_month: string (nullable = true)\n |-- issue_month: string (nullable = true)\n |-- count: long (nullable = false)\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["root\n |-- completion_month: string (nullable = true)\n |-- issue_month: string (nullable = true)\n |-- count: long (nullable = false)\n\n"]}}],"execution_count":0},{"cell_type":"code","source":["sorted_completed_studiesDF.select('completion_month','count').show(truncate=False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"84bad62d-855c-4e7b-9427-99da8621aaba"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"+----------------+-----+\n|completion_month|count|\n+----------------+-----+\n|Jan             |1131 |\n|Feb             |934  |\n|Mar             |1227 |\n|Apr             |967  |\n|May             |984  |\n|Jun             |1094 |\n|Jul             |819  |\n|Aug             |700  |\n|Sep             |528  |\n|Oct             |187  |\n+----------------+-----+\n\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["+----------------+-----+\n|completion_month|count|\n+----------------+-----+\n|Jan             |1131 |\n|Feb             |934  |\n|Mar             |1227 |\n|Apr             |967  |\n|May             |984  |\n|Jun             |1094 |\n|Jul             |819  |\n|Aug             |700  |\n|Sep             |528  |\n|Oct             |187  |\n+----------------+-----+\n\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["### Visualization"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"888b2a7d-896c-4beb-9373-49929f692ec0"}}},{"cell_type":"code","source":["month_list = list(\n    sorted_completed_studiesDF.select('completion_month').toPandas()['completion_month']\n)\n\ncounter_list = list(\n    sorted_completed_studiesDF.select('count').toPandas()['count']\n)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"9a393ebb-8fe0-4361-9ad3-fa140475b834"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["import matplotlib.pyplot as plt\nfig, ax = plt.subplots()\nax.plot(month_list, counter_list);"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7ecd29c4-31c4-4e9b-9058-2b50ac23cb3f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":["plt.bar(month_list, counter_list)\nplt.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"9539b810-236a-43a0-9dce-f0fa8eff772e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"cw-assignment","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{"YEAR":{"nuid":"79299b02-82d7-4d95-919c-3f4bffa71795","currentValue":"2021","widgetInfo":{"widgetType":"dropdown","name":"YEAR","defaultValue":"2021","label":null,"options":{"widgetType":"dropdown","choices":["2019","2020","2021"]}}}},"notebookOrigID":966858732572298}},"nbformat":4,"nbformat_minor":0}
